ArticleBritish journal of clinical pharmacology2012
Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.
Article in British journal of clinical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Denoised MDS-UPDRS part-III scores yield new patterns of progression heterogeneity in early stage Parkinson's disease.NPJ Parkinson's disease · 2026Article
- Denoised MDS-UPDRS Part-III Scores Yield New Patterns of Progression Heterogeneity in Early Stage Parkinson's Disease.bioRxiv : the preprint server for biology · 2026Article
- The Effects of Repetitive Transcranial Magnetic Stimulation on Gait, Motor Function, and Balance in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Journal of clinical medicine · 2025Review
- Different associated factors of subjective cognitive complaints in patients with early and advanced Parkinson's disease.Frontiers in aging neuroscience · 2023Article
- Transcriptome Analysis Reveals a Two-Gene Signature Links to Motor Progression and Alterations of Immune Cells in Parkinson's Disease.Journal of Parkinson's disease · 2023Article
- Aberrant functional connectivity and activity in Parkinson's disease and comorbidity with depression based on radiomic analysis.Brain and behavior · 2021Article
- Prognostic predictors relevant to end-of-life palliative care in Parkinson's disease and related disorders: a systematic review.Journal of neurology, neurosurgery, and psychiatry · 2021Review
- A Radiomics Approach to Predicting Parkinson's Disease by Incorporating Whole-Brain Functional Activity and Gray Matter Structure.Frontiers in neuroscience · 2020Article
- A modeling and simulation-based assessment of the impact of confounding factors on the readout of a sildenafil survival trial in pulmonary arterial hypertension.Journal of pharmacokinetics and pharmacodynamics · 2019Article
- Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson's Disease Rating Scales.Pharmaceutical research · 2019Article
- Clinical Profile of Chinese Long-Term Parkinson's Disease Survivors With 10 Years of Disease Duration and Beyond.Aging and disease · 2018Article
- Development and validation of prognostic survival models in newly diagnosed Parkinson's disease.Movement disorders : official journal of the Movement Disorder Society · 2018Article
- Item Response Theory as an Efficient Tool to Describe a Heterogeneous Clinical Rating Scale in De Novo Idiopathic Parkinson's Disease Patients.Pharmaceutical research · 2017Article
- Dynamics of change in self-reported disability among persons with Parkinson's disease after 2 years of follow-up.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Article
- Parkinson's Disease Severity at 3 Years Can Be Predicted from Non-Motor Symptoms at Baseline.Frontiers in neurology · 2017Article
- Application of a hazard-based visual predictive check to evaluate parametric hazard models.Journal of pharmacokinetics and pharmacodynamics · 2016Article
- Impact of Depression on Progression of Impairment and Disability in Early Parkinson's Disease.Movement disorders clinical practice · 2015Article
- Clinical pharmacology = disease progression + drug action.British journal of clinical pharmacology · 2015Review
- Disease progression and neuroscience.Journal of pharmacokinetics and pharmacodynamics · 2013Review
- A time to event tutorial for pharmacometricians.CPT: pharmacometrics & systems pharmacology · 2013Article
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo describe the time to clinical events (death, disability, cognitive impairment and depression) in Parkinson's disease using the time course of disease status and treatment as explanatory variables.
methodsDisease status based on the Unified Parkinson's Disease Rating Scale (UPDRS) and the time to clinical outcome events were obtained from 800 patients who initially had early Parkinson's disease. Parametric hazard models were used to describe the time to the events of interest.
resultsTime course of disease status (severity) was an important predictor of clinical outcome events. There was an increased hazard ratio for death 1.4 (95% CI 1.31, 149), disability 2.75 (95% CI 2.30, 3.28), cognitive impairment 4.35 (95% CI 1.94, 9.74), and depressive state 1.43 (95% CI 1.26, 1.63) with each 10 unit increase of UPDRS. Age at study entry increased the hazard with hazard ratios of 49.1 (95% CI 8.7, 278) for death, 4.76 (95% CI 1.10, 20.6) for disability and 90.0 (95% CI 63.3-128) for cognitive impairment at age 60 years. Selegiline treatment had independent effects as a predictor of death at 8 year follow-up with a hazard ratio of 2.54 (95% CI 1.51, 4.25) but had beneficial effects on disability with a hazard ratio of 0.363 (95% CI 0.132, 0.533) and depression with a hazard ratio of 0.372 (95% CI 0.12, 0.552).
conclusionsOur findings show that the time course of disease status based on UPDRS is a much better predictor of future clinical events than any baseline disease characteristic. Continued selegiline treatment appears to increase the hazard of death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.